Identification of genes that mediate sensitivity to cisplatin
- PMID: 11723219
Identification of genes that mediate sensitivity to cisplatin
Abstract
Cisplatin (cDDP) is effective against some human tumors, but many are intrinsically resistant and, even among initially sensitive tumors, acquired resistance develops commonly during treatment. It has not been possible to prove which biochemical mechanisms control sensitivity to cDDP. Gene knockout studies in yeast, Dictyostelium discoideum, and mammalian cells have begun to unambiguously identify genes whose products function to modulate the cytotoxicity of cDDP. This review summarizes information currently available about the function of these genes. This comprehensive compilation points to the involvement of regulatory pathways known to mediate apoptosis, cell cycle checkpoint activation, and transcriptional rescue as regulators of cDDP sensitivity. Elucidation of the molecular mechanisms that mediate cDDP resistance holds promise for the design of pharmacological strategies for preventing, overcoming, or reversing this form of drug resistance.
Similar articles
-
Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.Cancer Chemother Pharmacol. 2003 Jun;51(6):505-11. doi: 10.1007/s00280-003-0614-z. Epub 2003 Apr 23. Cancer Chemother Pharmacol. 2003. PMID: 12709826
-
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.Cancer Res. 2007 Jul 1;67(13):6325-32. doi: 10.1158/0008-5472.CAN-06-4261. Cancer Res. 2007. PMID: 17616691
-
[Cell signaling and CDDP resistance].Gan To Kagaku Ryoho. 1997 Feb;24(4):424-30. Gan To Kagaku Ryoho. 1997. PMID: 9063479 Review. Japanese.
-
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.Biochem Pharmacol. 2007 Jun 30;74(1):20-7. doi: 10.1016/j.bcp.2007.03.025. Epub 2007 Mar 30. Biochem Pharmacol. 2007. PMID: 17466278
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance.Oncogene. 2003 Oct 20;22(47):7265-79. doi: 10.1038/sj.onc.1206933. Oncogene. 2003. PMID: 14576837 Review.
Cited by
-
Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae.Mol Pharmacol. 2008 Oct;74(4):1092-100. doi: 10.1124/mol.108.048256. Epub 2008 Jul 8. Mol Pharmacol. 2008. PMID: 18612078 Free PMC article.
-
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.J Cell Physiol. 2010 Nov;225(3):822-8. doi: 10.1002/jcp.22287. J Cell Physiol. 2010. PMID: 20589834 Free PMC article.
-
Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.Int J Mol Sci. 2018 Mar 7;19(3):767. doi: 10.3390/ijms19030767. Int J Mol Sci. 2018. PMID: 29518977 Free PMC article.
-
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.BMC Cancer. 2016 Jul 13;16:470. doi: 10.1186/s12885-016-2527-3. BMC Cancer. 2016. PMID: 27411790 Free PMC article.
-
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin.Mol Pharm. 2012 Jun 4;9(6):1822-33. doi: 10.1021/mp300153z. Epub 2012 May 17. Mol Pharm. 2012. PMID: 22571463 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources